Welcome to our dedicated page for HealWELL AI news (Ticker: HWAIF), a resource for investors and traders seeking the latest updates and insights on HealWELL AI stock.
HEALWELL AI Inc. (OTCQX: HWAIF; TSX: AIDX) regularly issues news updates as a healthcare artificial intelligence company focused on preventative care and early disease detection. Its announcements describe how the company is developing and commercializing proprietary clinical decision support systems and AI platforms intended to help healthcare providers detect rare and chronic diseases, improve efficiency, and support better patient outcomes.
News releases from HEALWELL cover a range of topics, including financial and operational updates, strategic acquisitions and divestments, and progress in integrating acquired businesses such as Orion Health. The company has reported a transition toward a pure-play digital SaaS, services and AI business focused on health systems and large enterprise customers, and its news flow reflects this emphasis on enterprise-grade healthcare software and data science offerings.
HEALWELL’s news also highlights developments in its AI platforms, including the DARWEN™ AI system and the launch of AmadeusAI, an AI-enabled digital care record built on Orion Health’s Amadeus platform. Announcements have described new AI tools such as SMARTSearch, SMARTSummary, and SMARTIdentify, as well as collaborations with public health organizations, healthcare systems, and life sciences partners.
Investors and observers can use this news page to follow HEALWELL’s disclosures on corporate transactions, joint ventures, memoranda of understanding, recognition of its AI technologies in peer-reviewed studies, and participation in industry and investment conferences. The updates provide context on how the company presents its strategy in preventative healthcare AI, its focus on real-world data and evidence generation, and its orientation toward large-scale health system and enterprise deployments.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) reported record quarterly revenue of $5.44 million in Q2-2024, a 205% increase from Q2-2023. The company also achieved net income of $2.54 million, compared to a loss of $9.81 million in Q2-2023. This turnaround was primarily due to settling past liabilities and successful equity financing of $20 million.
Key highlights include:
- Adjusted Gross Profit of $3.76 million, up 669% year-over-year
- Adjusted Gross Margin of 69%, up from 27% in Q2-2023
- Cash balance of $19.82 million as of June 30, 2024
- Acquisition of BioPharma Services Inc. and Verosource Solutions Inc. on July 1, 2024
HEALWELL aims to reach a revenue run-rate approaching $100 million by year-end, driven by M&A activities and increased adoption of its AI-powered healthcare solutions.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, has announced it will release its Fiscal Second Quarter 2024 financial results for the period ended June 30, 2024, on Monday, August 12, 2024. The company will hold a conference call and simultaneous webcast to discuss its results on the same day at 5:30 pm EST (2:30 pm PST).
The call will be hosted by Dr. Alexander Dobranowski, Chief Executive Officer, and Anthony Lam, Chief Financial Officer. Attendees can join via webcast or phone, with pre-registration required for phone participation. The company has provided links for both webcast access and phone registration.
HEALWELL AI Inc.'s subsidiary, Intrahealth, has secured a $9 million, 7-year contract with the New Zealand Department of Corrections to implement a new patient management system for offender healthcare. This partnership aims to improve operational efficiency in prison healthcare by automating tasks, reducing paperwork, and simplifying processes. The system will feature advanced security protocols to ensure the confidentiality of medical information.
Intrahealth's technology is tailored to meet the specific needs of the prison context, going beyond traditional community healthcare systems. This collaboration represents a significant advancement in prisoner healthcare record management, potentially freeing up health teams to focus more on providing quality patient care.
HEALWELL AI's subsidiary VeroSource Solutions has launched a new Patient Summary feature in the MyHealthNB mobile app for the Province of New Brunswick. This innovative tool allows users to create and securely share a summary of their medical information, including medications, immunizations, lab results, and imaging reports. The feature aims to promote informed decision-making, modernize healthcare interactions, and reduce the burden on health system resources.
New Brunswick is the first province in Canada to offer this functionality, enabling its ~800,000 citizens to access approximately 12 months of health records. The Patient Summary aligns with the pan-Canadian Patient Summary Specification and can be particularly useful for medical emergencies, walk-in clinic visits, and when traveling across provincial or international borders.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), a healthcare technology company, has provided a corporate update on its capital allocation program and value creation strategy. The company aims to achieve run rate revenues of nearly $100 million by year-end, up from the current $65 million. This goal is supported by a robust M&A pipeline, including one signed LOI.
HEALWELL's four acquisitions have positioned it to leverage health data with AI for three key stakeholder groups: clinicians, large enterprises, and the pharmaceutical industry. The company plans to continue growing both organically and inorganically, focusing on early disease detection AI capabilities and mature healthcare software companies.
HEALWELL recently strengthened its balance sheet by reducing total liabilities by $15.5 million and had cash exceeding $14.5 million at Q2 end. If all in-the-money warrants are exercised, the cash balance could grow to over $39 million.
WELL Health Technologies Corp. and HEALWELL AI Inc. have jointly launched an AI-powered co-pilot for cardiologists to improve detection of cardiovascular disease (CVD). This tool, an extension of WELL AI Decision Support (WAIDS), will be deployed in WELL Diagnostic Centres, Canada's largest cardiology and medical diagnostic group with over 40 locations in Ontario.
The co-pilot aims to assist cardiologists in identifying high-risk CVD patients, addressing a critical health issue that accounts for 32% of global deaths. This technology is expected to enhance preventative care, improve patient outcomes, and reduce healthcare costs. Additionally, HEALWELL plans to leverage this technology to accelerate life sciences research and development opportunities related to CVD, potentially tapping into the growing global market for cardiovascular drugs, projected to reach USD 207.8 billion by 2033.
HEALWELL has improved its balance sheet significantly in Q2 2024 by reducing total liabilities by approximately $15.5 million.
The reduction includes $3.9 million in future liabilities and $2.5 million in arrears payments related to MCI Ontario, $7.9 million in loan forgiveness from First Canadian Wellness, and $1.3 million from eliminating a Put option liability by acquiring the remaining 20% interest in PolyClinic.
HEALWELL now owns 100% of PolyClinic, aligning it with its recent acquisition of BioPharma to foster growth in clinical research. The company has a cash balance of approximately $14.5 million, which could rise to $39 million if all outstanding in-the-money warrants are exercised.
HEALWELL's remaining debt includes $11.6 million in convertible debentures and loans from FedDev and BDC, which could convert into equity, further reducing debt.
HEALWELL AI has successfully closed acquisitions of VeroSource Solutions and BioPharma Services, enhancing its financial and operational profile. The deals increase HEALWELL's annual revenue run-rate to over $65 million. VeroSource, serving multiple provincial health clients, provides cloud-based data interoperability platforms, while BioPharma, a leading CRO, has completed over 2,200 clinical trials. The acquisitions were completed for a combined consideration of $32.1 million, including earn-outs. The integration is expected to bring significant synergies, leveraging HEALWELL's AI capabilities to enhance healthcare data management and clinical research offerings. CEO Dr. Alexander Dobranowski emphasized the strategic fit and potential for improved patient outcomes through advanced technology.
HEALWELL AI has made a $2,000,000 strategic investment into xAI, an AI company founded by Elon Musk, through the Think 1st Principles (T1P) investment fund. This investment is designed to accelerate HEALWELL's development of healthcare-focused large language models by leveraging xAI's resources and expertise. The partnership grants HEALWELL access to the closed xAI Developer Program, which aims to enhance product development capabilities using advanced technical tools and unique datasets. The investment is facilitated by Massimo Agostinelli of the Agostinelli Family Office, offering HEALWELL a unique opportunity to integrate with the Muskonomy ecosystem.
HEALWELL AI's subsidiary, Pentavere, has demonstrated the efficacy of its DARWEN AI system in identifying patients with radiotherapy-related toxicities through a collaboration with Princess Margaret Cancer Centre. This AI-driven approach significantly enhances the early detection of severe toxicities in cancer patients, potentially improving their quality of life and survival. The findings will be presented at the American Society for Radiation Oncology on September 29th and the Canadian Association of Radiation Oncology on September 11th. This collaboration highlights the potential of AI-powered clinical decision support in providing critical insights for oncological decision-making.